Plain-English translation of NCT07330778 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called , which is designed to target two proteins involved in asthma inflammation. The study will give a single injection to people with mild to moderate asthma and monitor them carefully to see how safe the medication is and how their bodies respond to it.
Current asthma treatments don't work well enough for everyone, and researchers are looking for new ways to reduce the inflammation that causes asthma symptoms. This trial is testing whether targeting specific immune system proteins could offer a better treatment option.
You likely qualify if…
You likely don't qualify if…
If you are selected, you will receive a single intravenous infusion of the medication at the study center. After that, you will return for follow-up visits over the next 12 weeks so the researchers can check how you are doing, run blood tests, and monitor for any side effects. The whole study lasts about 3 months from start to finish.
AI-generated summary from trial data · Jul 13, 2026 · Not medical advice
United States